Skip to Content
MilliporeSigma
  • Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Brain : a journal of neurology (1988-08-01)
D H Miller, P Rudge, G Johnson, B E Kendall, D G Macmanus, I F Moseley, D Barnes, W I McDonald
ABSTRACT

Serial gadolinium-DTPA (Gd-DTPA) enhanced magnetic resonance imaging (MRI) was performed in 9 patients with multiple sclerosis (MS). On the first scan enhancing lesions were seen in 7 patients, all of whom were in acute relapse. Most enhancing lesions were asymptomatic. On the second scan (3 to 5 weeks later), persisting enhancement was seen in only 12/54 lesions which enhanced on the first scan. No lesion showed persisting enhancement on the third scan (after 6 months). Enhancement occurred in all 12 new lesion areas seen on the unenhanced second scan and in 8 of 15 new lesions seen on the third scan. Enhancement was also seen in 4 older lesions which had been nonenhancing on earlier scans. Relaxation time measurements demonstrated a high water content in some nonenhancing lesions, which could be due to a subtle blood-brain barrier disturbance not detected with Gd-DTPA. The results show that blood-brain barrier impairment is a consistent finding in new MS lesions detected with MRI. Gd-DTPA is a useful marker of new and biologically active lesions and should prove of value in monitoring therapeutic trials in MS.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diethylenetriaminepentaacetic acid gadolinium(III) dihydrogen salt hydrate, 97%